Crispr Therapeutics AG vs SoFi Technologies Inc — how do they compare? Crispr Therapeutics AG trades at $54.31 (market cap $5.23B), while SoFi Technologies Inc trades at $18.19 (market cap $23.22B). The key difference: SoFi Technologies Inc is far larger — about 4.4× Crispr Therapeutics AG's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, SoFi Technologies Inc nearer its low. Which is the better fit depends on your goals.
| CRSP | SOFI | |
|---|---|---|
Market Cap | $5.23B | $23.22B |
Sector | Health | Financials |
52-Week High | $76.78 | $32.21 |
52-Week Low | $44.34 | $15.15 |
Enterprise Value | $3.65B | — |
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
SOFI trades at $18.12, down 1.41% today, with a bullish technical signal and recent earnings beats. Revenue grew to $3.61B in 2025, with a net income margin of 14.78%. The stock is supported by strong member growth and a consensus price target of $19.50, though negative operating cash flow and high valuation ratios present challenges.
Outlook is cautiously optimistic with growth potential from digital banking expansion, but risks include persistent negative cash flow, competitive pressures, and sensitivity to interest rate changes. Analyst sentiment is mixed, with 33% buy ratings highlighting upside, while high P/E of 36.69 warrants caution for value-focused investors.
Trailing returns across standard periods
Latest headlines on both assets
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →